BlackRock Institutional Trust Company, N.A. - BRAINSTORM CELL THERAPEUTICS ownership

BRAINSTORM CELL THERAPEUTICS's ticker is BCLI and the CUSIP is 10501E201. A total of 27 filers reported holding BRAINSTORM CELL THERAPEUTICS in Q4 2016. The put-call ratio across all filers is - and the average weighting 0.0%.

Quarter-by-quarter ownership
BlackRock Institutional Trust Company, N.A. ownership history of BRAINSTORM CELL THERAPEUTICS
ValueSharesWeighting
Q4 2016$63,000
+5.0%
24,7890.0%0.00%
Q3 2016$60,0000.0%24,7890.0%0.00%
Q2 2016$60,000
-9.1%
24,7890.0%0.00%
Q1 2016$66,000
-7.0%
24,7890.0%0.00%
Q4 2015$71,000
+24.6%
24,7890.0%0.00%
Q3 2015$57,000
-36.0%
24,7890.0%0.00%
Q2 2015$89,00024,7890.00%
Other shareholders
BRAINSTORM CELL THERAPEUTICS shareholders Q4 2016
NameSharesValueWeighting ↓
SABBY MANAGEMENT, LLC 242,850$923,0000.13%
ABNER HERRMAN & BROCK LLC 241,500$918,0000.13%
Weaver Consulting Group 48,881$186,0000.10%
Tibra Equities Europe Ltd 87,000$331,0000.10%
Ikarian Capital, LLC 293,200$1,115,0000.09%
GSA CAPITAL PARTNERS LLP 60,238$229,0000.03%
Ergoteles LLC 124,329$472,0000.01%
CFO4Life Group, LLC 12,003$46,0000.01%
HighPoint Advisor Group LLC 17,033$65,0000.01%
BOOTHBAY FUND MANAGEMENT, LLC 32,836$125,0000.00%
View complete list of BRAINSTORM CELL THERAPEUTICS shareholders